L Andritsos, R Furman, IW Flinn, A Foreno-Torres, K Foon, JM Flynn, SC Stromatt, JC Byrd. A Phase 1 trial of TRU-016, an anti-CD37 Small Modular Immunopharmaceutical (SMIP™) protein in relapsed and refractory CLL: Early promising clinical activity. ASH 2009, poster presentation.

S Rafiq, C Cheney, P A. Thompson, T Siadak, P Algate, C Cerveneny, JC. Byrd and N Muthusamy. Glycovariant CD37 Small Modular Immuno-pharmaceutical (SMIP™) promotes enhanced Natural killer cell mediated cytotoxicity against primary chronic lymphocytic leukemia cells. ASH 2009, poster presentation. 

LA Andritos, R Furman, IW Flinn, A Forero-Torres, JM Flynn, SC Stromatt, JC Byrd. A Phase 1 Trial of TRU-016, an anti-CD37 Small Modular Immunopharmaceutical (SMIP™) in Relapsed and Refractory CLL. ASCO 2009, poster presentation.

PR Baum, C Cerveny, B Gordon, C Nilsson, J Wiens, S Rafiq, R Lapalombella, N Muthusamy, JC Byrd and A Wahl. Evaluation of the effect of TRU-016, an anti-CD37 directed SMIP™, in combination with other therapeutic drugs in models of Non-Hodgkin's Lymphoma. ASCO 2009, poster presentation.

R Lapalombella, A Ramanunni, LA Andritsos, J M Flynn, P Baum, P Thompson, N Muthusamy*, and JC Byrd*. *co-senior authors. Effect of CD37 small modular immuno-pharmaceutical (SMIP™) on direct apoptosis in chronic lymphocytic leukemia cells via transcriptional up-regulation of the BH3 family member BIM. ASCO 2009, poster presentation.

C Cerveny, L Grosmarie, C Nilsson, R Bade, R Lowe, L Kicknosway, A Simon, W Brady, M Kennedy, P Baum. In Vitro and In Vivo Anti-B Cell Lymphoma Activities of TRU-016. ASCO 2008, poster presentation.

X Zhao, R Lapalombella, T Joshi, C Cheney, A Gowda, MS Hayden-Ledbetter, PR Baum, TS Lin, D Jarjoura, A Lehman, D Kussewitt, RJ Lee, MA Caligiuri, S Tridandapani, N Muthusamy, and JC Byrd. Targeting CD37-positive lymphoid malignancies with novel engineered small modular immunopharmaceutical. Byrd manuscript.